Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2 + Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis

(2022) Worapol Ngamcherdtrakul et al.   Small

In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response

(2021) Worapol Ngamcherdtrakul et al.   ADVANCED MATERIALS

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle

(2020) Yuan Zhuang et al.   OncoTargets and Therapy

Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy

(2020) Josephine Hai et al.   CLINICAL CANCER RESEARCH

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53

(2019) Jolien Van den Bossche et al.   Molecular Oncology

Immunotherapy and targeted therapy combinations in metastatic breast cancer

(2019) Francisco J Esteva et al.   LANCET ONCOLOGY

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

(2019) Ratnakar Singh et al.   EMBO Molecular Medicine

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

(2019) Thijs S Stutvoet et al.   JOURNAL OF PATHOLOGY

PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer

(2019) Moataz Reda et al.   CANCER LETTERS

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery

(2018) Worapol Ngamcherdtrakul et al.   International Journal of Nanomedicine

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

(2018) Ioannis Zerdes et al.   ONCOGENE

Cold Atmospheric Plasma Induces ATP-Dependent Endocytosis of Nanoparticles and Synergistic U373MG Cancer Cell Death

(2018) Zhonglei He et al.   Scientific Reports

Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.

(2018) Kerry Lynn Reynolds et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment

(2018) Mengyuan Li et al.   Journal of Oncology

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform

(2017) Jingga Morry et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

PLK1, A Potential Target for Cancer Therapy

(2017) Zhixian Liu et al.   Translational Oncology

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

(2016) Rosie Elizabeth Ann Gutteridge et al.   MOLECULAR CANCER THERAPEUTICS

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations

(2016) Yuehong Wang et al.   Oncotarget

Therapeutic siRNA for drug-resistant HER2-positive breast cancer

(2016) Shenda Gu et al.   Oncotarget

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+Breast Cancer

(2015) Worapol Ngamcherdtrakul et al.   ADVANCED FUNCTIONAL MATERIALS

Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells

(2015) Minji Choi et al.   CANCER LETTERS

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer

(2015) R. Ferrarotto et al.   CLINICAL CANCER RESEARCH

Programmed death-1 & its ligands: promising targets for cancer immunotherapy

(2015) Rajeev K Shrimali et al.   Immunotherapy

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Theranostic Mesoporous Silica Nanoparticles Biodegrade after Pro-Survival Drug Delivery and Ultrasound/Magnetic Resonance Imaging of Stem Cells

(2015) Paul J. Kempen et al.   Theranostics

Biodegradable and Renal Clearable Inorganic Nanoparticles

(2015) Emily B. Ehlerding et al.   Advanced Science

Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer

(2015) Joshua A. McCarroll et al.   Oncotarget

Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway

(2014) Wenrong Gong et al.   JOURNAL OF CHEMOTHERAPY

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Reciprocal Activation Between PLK1 and Stat3 Contributes to Survival and Proliferation of Esophageal Cancer Cells

(2011) Yu Zhang et al.   GASTROENTEROLOGY

Understanding biophysicochemical interactions at the nano–bio interface

(2009) Andre E. Nel et al.   NATURE MATERIALS